Zibb.com: Amgen Incorporated (Industry News & Blogs)

Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awa...

Tue, 24 Nov 2009 01:00:00 GMT

THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate?? (romiplostim), at a Nov. 18 ceremony in London. The Best Overa

Amgen Continues to Leverage ImmunoGen's TAP Technology - Zibb.com

Mon, 23 Nov 2009 23:33:01 GMT

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products, announced that Amgen Inc. has licensed the exclusive right to use the Company's maytansinoid Targeted Antibody Paylod (TAP) technology to develop anticancer therapeutics to an undisclosed target. This is the second

Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awa...

Mon, 23 Nov 2009 20:05:00 GMT

THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for Nplate® (romiplostim), at a Nov. 18 ceremony in London.

PRIMECAP Management Top Purchases: Amgen Inc., The Boeing Company...

Sun, 22 Nov 2009 15:43:34 GMT

GuruFocus tracks the stock buys, sells and commentaries of stock investment gurus such as Warren Buffett, George Soros, the best investors.

Amgen to Apply ImmunoGen TAP Technology to Another Cancer Target

Fri, 20 Nov 2009 00:00:00 GMT

Amgen licensed the exclusive right to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology to develop anticancer therapeutics to an undisclosed target. Thi

ImmunoGen Licenses Technology to Amgen for $1M

Thu, 19 Nov 2009 21:42:05 GMT

Immunogen develops cancer treatments using its Tumor-Activated Prodrug, or TAP, technology. The technology uses antibodies to deliver a killer agent to a cell. It is part of a larger movement to develop more accurate cancer therapies that can target and neutralize specific cells.

ImmunoGen Nabs $1M From Amgen

Thu, 19 Nov 2009 21:14:14 GMT

Waltham, MA-based ImmunoGen (NASDAQ: ]) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen's technology for linking

Amgen lawsuit highlights industry practice of overfilling vials.

Tue, 10 Nov 2009 16:09:35 GMT

VCSTAR: A lawsuit launched against Amgen Inc. on Oct. 30 raises important questions about what is accepted practice when it comes to manufacturing and administering certain drugs and whether the company encouraged the fraudulent sale of free drugs to increase their use.

Biotechnology Business: Studies from Amgen, Inc. update current d...

Mon, 09 Nov 2009 12:52:47 GMT

Biotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directory

Mixed Results For Amgen’s Latest Vectibix Trial

Thu, 05 Nov 2009 20:28:15 GMT

Vectibix, the new colon cancer drug made by drug-maker Amgen (AMGN) did not show statistically significant survival of patients in its most recent study.

Is Amgen retreat a case of investor overreaction?

Thu, 05 Nov 2009 17:42:00 GMT

Amgen shares have taken a beating in recent weeks over news that hotly anticipated bone-loss drug Prolia is faced with regulatory snags, but are investors’ fears well-founded? And, can the biotech regain its status as a growth-story stock?

Amgen Announces Overall Survival Results for Vectibix(R) in First...

Thu, 05 Nov 2009 12:00:00 GMT

Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.

Amgen's cancer drug fails to increase overall survival rate

Thu, 05 Nov 2009 11:30:00 GMT

Despite prolonging survival without disease progression in patients with metastatic colorectal cancer, an investigational drug from Amgen failed to increase overall survival in a late-stage clinical trial, the biotech company said Thursday.

Personal Injury and Social Security Disability Blog: Amgen Accuse...

Mon, 02 Nov 2009 15:38:23 GMT

The New York Times reported, "The biotechnology giant Amgen has been accused by New York and some other states of engaging in illegal kickbacks to promote sales of its anemia drug Aranesp [darbepoetin alfa]." The states filed a lawsuit Friday...

Michigan and 14 other states sue Amgen alleging kickback scheme

Sun, 01 Nov 2009 19:13:00 GMT

Biotechnology behemoth Amgen Inc. is being sued by Michigan and 14 other states alleging the company gave kickbacks to medical providers to help boost sales of the anemia drug Aranesp.

Amgen sued over Anemia drug - The Money Times

Sun, 01 Nov 2009 12:04:13 GMT

The lawsuit was filed in U.S. District Court in New York and announced by New York Attorney General Andrew Cuomo. The suit asserts that Amgen was involved with two other companies-- International Nephrology Network (INN), a specialty group-purchasing organization, and ASD Healthcare, a wholesaler

Amgen sued by California and 14 other states over anemia drug - L...

Sat, 31 Oct 2009 13:46:49 GMT

New York, California and 13 other states are accusing biotech giant Amgen Inc. of offering kickbacks to medical providers to boost sales across the country of its anemia drug Aranesp, which increasingly has been beset by safety concerns.

State AGs suing U.S. drug maker Amgen - UPI.com

Sat, 31 Oct 2009 13:33:38 GMT

Several state attorneys general allege the U.S. biotechnology firm Amgen Inc. has engaged in illegal kickbacks to help sales of its anemia drug Aranesp.

Researchers question anemia drug benefits - Boston Globe

Sat, 31 Oct 2009 06:14:41 GMT

A drug commonly prescribed to treat anemia in patients with both type 2 diabetes and kidney disease worked no better than a placebo in reducing deaths or cardiovascular problems it was thought to prevent, according to a paper published online last night. Instead, people who took the drug, Aranesp,

Amgen's Anemic Results

Sat, 31 Oct 2009 01:40:00 GMT

The company's best-selling Aranesp drug doubles the risk that kidney patients will suffer a stroke.

15 states sue Amgen alleging kickback scheme

Sat, 31 Oct 2009 01:07:10 GMT

Biotechnology behemoth Amgen Inc. is being sued by 15 states alleging the company gave kickbacks to medical providers to help boost sales of the anemia drug Aranesp. The New York Attorney General's office says it and 15 states allege the Thousand Oaks, Calif.

States Claim Amgen Paid Doctors to Write Prescriptions - WSJ.com

Fri, 30 Oct 2009 20:24:13 GMT

New York alleges drug sellers provided weekend retreats, other incentives to prescribe anemia drug.

Amgen Sued by States Over Kickback Scheme, Cuomo Says - Bloomberg

Fri, 30 Oct 2009 19:56:05 GMT

[bn:WBTKR=AMGN:US] Amgen Inc. [], the world’s largest biotechnology company, was sued by New York and 14 other states following an investigation into a nationwide kickback scheme to boost drug sales, New York Attorney General [bn:PRSN=1] Andrew Cuomo [] said.

15 states sue Amgen alleging kickback scheme

Fri, 30 Oct 2009 18:36:56 GMT

(10-30) 11:36 PDT New York (AP) -- Biotechnology behemoth Amgen Inc. is being sued by 15 states alleging the company gave kickbacks to medical providers to help boost sales of the anemia drug Aranesp. The New York Attorney General's office...

15 states sue Amgen alleging kickback scheme | R&D Mag

Fri, 30 Oct 2009 18:25:57 GMT

Biotechnology behemoth Amgen Inc. is being sued by 15 states alleging a scheme of kickbacks to medical providers to help boost sales of the anemia drug Aranesp. The New York Attorney General's office says it and 15 states allege the South San Francisco, Calif.